X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs LUPIN LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA LUPIN LTD GSK PHARMA/
LUPIN LTD
 
P/E (TTM) x 60.1 17.5 342.8% View Chart
P/BV x 11.8 4.1 288.6% View Chart
Dividend Yield % 2.1 0.8 277.4%  

Financials

 GSK PHARMA   LUPIN LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
LUPIN LTD
Mar-16
GSK PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3,8502,127 181.0%   
Low Rs2,9661,294 229.2%   
Sales per share (Unadj.) Rs332.3304.1 109.3%  
Earnings per share (Unadj.) Rs44.350.4 87.9%  
Cash flow per share (Unadj.) Rs47.260.7 77.8%  
Dividends per share (Unadj.) Rs50.007.50 666.7%  
Dividend yield (eoy) %1.50.4 334.6%  
Book value per share (Unadj.) Rs202.7243.8 83.2%  
Shares outstanding (eoy) m84.70450.58 18.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.35.6 182.3%   
Avg P/E ratio x76.933.9 226.6%  
P/CF ratio (eoy) x72.228.2 256.0%  
Price / Book Value ratio x16.87.0 239.6%  
Dividend payout %112.914.9 758.4%   
Avg Mkt Cap Rs m288,643770,740 37.5%   
No. of employees `0004.616.4 28.2%   
Total wages/salary Rs m4,43421,077 21.0%   
Avg. sales/employee Rs Th6,104.58,379.6 72.8%   
Avg. wages/employee Rs Th961.61,289.0 74.6%   
Avg. net profit/employee Rs Th813.71,388.7 58.6%   
INCOME DATA
Net Sales Rs m28,148137,016 20.5%  
Other income Rs m1,2181,877 64.9%   
Total revenues Rs m29,366138,893 21.1%   
Gross profit Rs m4,77437,535 12.7%  
Depreciation Rs m2484,635 5.4%   
Interest Rs m0446 0.0%   
Profit before tax Rs m5,74434,330 16.7%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,01811,536 17.5%   
Profit after tax Rs m3,75222,707 16.5%  
Gross profit margin %17.027.4 61.9%  
Effective tax rate %35.133.6 104.6%   
Net profit margin %13.316.6 80.4%  
BALANCE SHEET DATA
Current assets Rs m21,46297,790 21.9%   
Current liabilities Rs m10,53653,872 19.6%   
Net working cap to sales %38.832.1 121.1%  
Current ratio x2.01.8 112.2%  
Inventory Days Days6885 79.9%  
Debtors Days Days16121 13.5%  
Net fixed assets Rs m4,71786,379 5.5%   
Share capital Rs m847901 94.0%   
"Free" reserves Rs m16,308105,735 15.4%   
Net worth Rs m17,171109,844 15.6%   
Long term debt Rs m1653,739 0.0%   
Total assets Rs m30,620224,378 13.6%  
Interest coverage xNM77.9-  
Debt to equity ratio x00.5 0.2%  
Sales to assets ratio x0.90.6 150.5%   
Return on assets %12.310.3 118.8%  
Return on equity %21.920.7 105.7%  
Return on capital %33.621.2 158.3%  
Exports to sales %049.1 0.0%   
Imports to sales %15.17.4 202.2%   
Exports (fob) Rs m467,244 0.0%   
Imports (cif) Rs m4,23710,199 41.5%   
Fx inflow Rs m51971,405 0.7%   
Fx outflow Rs m8,32017,807 46.7%   
Net fx Rs m-7,80153,598 -14.6%   
CASH FLOW
From Operations Rs m1,386-3,690 -37.6%  
From Investments Rs m5,010-69,434 -7.2%  
From Financial Activity Rs m-6,38358,126 -11.0%  
Net Cashflow Rs m12-14,998 -0.1%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 50.7 0.2 25,350.0%  
Indian inst/Mut Fund % 10.2 11.3 90.3%  
FIIs % 23.8 31.9 74.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.1 152.5%  
Shareholders   102,036 98,259 103.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ABBOTT INDIA  NATCO PHARMA  DIVIS LABORATORIES  IPCA LABS  ALKEM LABORATORIES  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 24, 2017 03:00 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS